NRSN | NeuroSense Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2500 - 1.4550
52 Week Range	0.4000 - 2.3300
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	334,056
Average Volume	404,877
Shares Outstanding	19,471,006
Market Cap	26,091,148
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-09

Valuation
Profitability
Growth
Health
P/E Ratio	-1.44
Forward P/E Ratio	N/A
EPS	-0.93
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	18
Country	Israel
Website	NRSN

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSN's peers: LOGC, QNRX, REVB, HILS, NRBO, VRAX, NTRB, LGVN, RNXT, BWV, KPRX, PXMD, ALLR, KRBP, BDRX, XRTX, SBFMW

*Chart delayed

Analyzing fundamentals for NRSN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NRSN Fundamentals page.

Watching at NRSN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NRSN Technicals page.